Myotonia congenita

1. High-Yield Summary

• Primary Channelopathy: Hereditary non-dystrophic skeletal muscle channelopathy caused by loss-of-function mutations in the CLCN1 gene (chromosome 7q35), which encodes the voltage-gated skeletal muscle chloride channel ClC-1.
• Pathognomonic Triad: Muscle stiffness (myotonia) with delayed muscular relaxation following voluntary contraction, generalized or lower-extremity muscle hypertrophy (“herculean habitus”), and the classic “warm-up phenomenon” where stiffness improves with repeated movement.
• Inheritance Variants: Autosomal dominant Thomsen disease (earlier infantile onset, milder disability, diffuse myotonia) versus autosomal recessive Becker disease (later childhood onset, marked calf hypertrophy, and characteristic transient weakness upon initiating maximal exertion).
• Diagnostic Benchmarks: Needle electromyography (EMG) demonstrating pathognomonic “dive-bomber” repetitive discharges, short exercise test showing transient post-exercise CMAP decrement (Pattern II), and confirmatory targeted CLCN1 molecular genetic testing.
• Critical Perioperative Mandate: Absolute contraindication to depolarizing neuromuscular blockade (succinylcholine), which triggers life-threatening sustained muscle spasm, severe rhabdomyolysis, and hyperkalemic arrest; first-line medical therapy is oral mexiletine.

2. Anatomy

Understanding the clinical manifestations of myotonia congenita requires precise comprehension of skeletal muscle membrane architecture and the appendicular muscular topography that frequently brings these patients to orthopaedic attention.

Sarcolemmal and Transverse Tubular Architecture

Skeletal muscle excitation-contraction coupling depends on the specialized architecture of the sarcolemma and its deep invaginations, the transverse tubular (T-tubular) system. The voltage-gated chloride channel ClC-1 resides predominantly within the sarcolemma and the transverse tubular membranes. In healthy resting human skeletal muscle, chloride conductance (gCl) accounts for 70% to 85% of total resting electrical conductance, maintaining resting membrane potential between -80 mV and -90 mV.

Musculoskeletal Distribution & Hypertrophic Topography

Muscular hypertrophy in myotonia congenita displays a characteristic appendicular and axial distribution. Unlike dystrophic myotonias (such as myotonic dystrophy type 1, which manifests with temporalis, masseter, and sternocleidomastoid wasting), myotonia congenita causes true muscle fiber hypertrophy due to continuous involuntary electrical afterdischarges:

• Lower Extremities: Prominent hypertrophy of the gastrocnemius-soleus complex, quadriceps femoris, and gluteal musculature. Hypertrophic calves produce the classical “herculean” or athletic silhouette, even in sedentary children.
• Upper Extremities and Trunk: Deltoid, biceps brachii, forearm wrist and finger flexor hypertrophy, with increased paraspinal bulk contributing to accentuated lumbar lordosis.

Surgical Danger Zones & Soft-Tissue Constraints

Persistent baseline muscle stiffness and chronic muscular tone subject the tendon calcaneus (Achilles tendon) complex to repetitive contracture forces. Pediatric patients frequently develop fixed equinus deformities. When surgical lengthening is indicated, key neurovascular danger zones include:

• Sural Nerve: Crosses the lateral border of the Achilles tendon approximately 8 to 10 cm proximal to the calcaneal tuberosity; at risk during percutaneous or open coronal Z-lengthening.
• Tibial Neurovascular Bundle: Located deep and medial to the flexor hallucis longus tendon within the deep posterior compartment; requires formal protection during extended medial posteromedial releases.

3. Pathogenesis

The fundamental electrophysiological defect in myotonia congenita is a failure of skeletal muscle sarcolemmal repolarization and electrical stabilization following voluntary mechanical contraction.

Normal Muscle Electrophysiology

During normal neuromuscular excitation, an action potential traveling down the T-tubule induces outward potassium (K+) flux into the restricted extracellular luminal space. In physiological states, high resting chloride conductance mediated by functional ClC-1 channels immediately shunts electrical current, clamping the sarcolemmal resting potential near the chloride equilibrium potential (-85 mV) and preventing tubular potassium accumulation from reaching the excitation threshold of voltage-gated sodium channels (Nav1.4).

The Chloride Conductance Failure

Mutations in the CLCN1 gene abolish or severely depress ClC-1 channel function, diminishing chloride conductance by 50% to over 80%. When gCl drops below approximately 30% of normal:

• Potassium ions accumulating within the narrow T-tubule lumen during voluntary activation are no longer counterbalanced by rapid chloride influx.
• The localized extracellular potassium buildup causes progressive depolarization of the T-tubular membrane.
• Depolarization reaches the threshold for opening Nav1.4 channels, firing involuntary, self-propagating trains of action potentials (“myotonic runs” or electrical afterdischarges) that outlast the cessation of voluntary motor nerve activity.

The Warm-Up Phenomenon and Transient Weakness

The two hallmarks of myotonia congenita demonstrate distinct biophysical mechanisms:

• The Warm-Up Phenomenon: Repetitive muscular contraction stimulates the electrogenic Na+/K+-ATPase pump and recruits slow voltage-gated potassium channels (e.g., Kv7/KCNQ), accelerating potassium clearance from the T-tubule lumen and re-establishing resting membrane stability. Consequently, myotonia diminishes after several consecutive movement cycles.
• Transient Weakness (Becker Disease): In severe recessive disease, sudden maximal effort produces overwhelming tubular depolarization that locks voltage-gated sodium channels in a state of fast and slow inactivation. The muscle fiber becomes temporarily electrically inexcitable, causing abrupt loss of force during the first few seconds of exertion that resolves as potassium is cleared and resting potential recovers.

4. Natural History

Myotonia congenita is a non-dystrophic disease with normal life expectancy, yet it causes substantial lifelong morbidity, functional limitation, and secondary musculoskeletal adaptations.

Epidemiology

The worldwide prevalence is estimated at 1 in 100,000 individuals, but reaches 1 in 10,000 in northern Scandinavia due to regional founder variants. Autosomal recessive Becker disease accounts for roughly two-thirds of cases, while autosomal dominant Thomsen disease represents the remaining one-third. Both sexes inherit the disease equally; however, males frequently present with greater functional impairment and more pronounced hypertrophy due to higher baseline muscle mass and androgenic modulation.

Chronological Progression

• Thomsen Disease: Onset typically occurs in infancy or early childhood (ages 0 to 4 years). Presenting signs include delayed eye opening after crying, feeding difficulties due to jaw stiffness, and motor clumsiness. The condition follows a benign, non-progressive course that remains stable throughout adult life.
• Becker Disease: Onset occurs later in childhood (ages 4 to 12 years). Symptoms initially affect the lower extremities (stiff gait, difficulty ascending stairs), progressing in adolescence to involve the upper limbs, trunk, and facial musculature. Symptoms typically plateau in early adulthood.

Long-Term Musculoskeletal Prognosis

Unlike dystrophic myotonias, patients do not suffer cardiac conduction blocks, cardiomyopathy, cataracts, or progressive muscle wasting. The primary long-term hazards are mechanical: recurrent falls resulting from transient weakness or cold-induced stiffness (predisposing to distal radius, ankle, or hip fractures), chronic exertional myalgia, and progressive equinus contractures from gastrocnemius hypertonicity.

5. Clinical Presentation

History

Patients and parents describe characteristic functional complaints:

• Action Myotonia: Difficulty releasing a handshake, opening jars, letting go of sports equipment, or opening eyes forcefully after sneezing.
• The “Stiff Start”: Severe stiffness when initiating gait after prolonged sitting; after taking several slow paces, gait becomes fluid and unrestricted (warm-up phenomenon).
• Environmental & Physiological Exacerbators: Cold exposure, emotional stress, physical fatigue, fasting, and pregnancy markedly aggravate muscle stiffness.
• Fall Episodes: In recessive Becker disease, patients describe sudden “locking up” or legs giving way when attempting to run across a street or accelerate suddenly, resulting in traumatic falls without loss of consciousness.

Physical Examination

Physical examination establishes the presence of action myotonia, percussion myotonia, and structural musculoskeletal alterations:

6. Imaging and Diagnostic Studies

The diagnostic workup combines electrophysiological testing, genetic confirmation, and targeted exclusion of dystrophic myopathies.

Needle Electromyography (EMG)

Needle EMG is the definitive neurophysiological investigation:

• Myotonic Runs: Spontaneous, high-frequency repetitive electrical discharges triggered by needle insertion, percussion, or voluntary contraction. Discharges display spontaneous waxing and waning of both amplitude (10 μV to 1 mV) and frequency (10 Hz to 80 Hz).
• The “Dive-Bomber” Sound: The audio monitor reproduces a classic acoustic tone resembling a diving World War II aircraft or revving engine, pathognomonic of myotonia.
• Normal Motor Unit Potentials: In pure myotonia congenita, motor unit action potentials (MUAPs) display normal configuration, duration, and recruitment, with no fibrillations or sharp waves at baseline.

Short Exercise Test (Fournier Protocol)

The short exercise test distinguishes chloride channelopathies from sodium channelopathies and periodic paralyses. Compound muscle action potentials (CMAPs) are recorded from the abductor digiti minimi following 10-second maximal isometric contractions:

• Pattern II (Diagnostic of CLCN1 Myotonia Congenita): Demonstrates an immediate, transient decrement in CMAP amplitude and area (often >30% to 50%) immediately following brief exercise, with complete recovery to baseline within 60 to 120 seconds.
• Pattern I / III: Typically seen in sodium channel mutations (paramyotonia congenita) or periodic paralyses, where exercise-induced decrements worsen with cooling or prolonged rest.

Targeted Molecular Genetic Testing

Definitive confirmation requires targeted sequence analysis and deletion/duplication testing (MLPA) of the CLCN1 gene on chromosome 7q35:

• Identifies heterozygous missense variants in autosomal dominant Thomsen disease.
• Identifies homozygous or compound heterozygous missense, nonsense, frameshift, or multiexon deletion variants in autosomal recessive Becker disease.

Serum Laboratory & Imaging Biomarkers

• Serum Creatine Kinase (CK): Normal to moderately elevated (1.5x to 4x the upper limit of normal), secondary to continuous muscular tension rather than primary dystrophic necrosis.
• Muscle Magnetic Resonance Imaging (MRI): Demonstrates symmetrical muscle belly hypertrophy without fatty infiltration, edema, or muscle replacement, cleanly differentiating myotonia congenita from myotonic dystrophy (DM1/DM2) and limb-girdle muscular dystrophies.
• Muscle Biopsy: Generally unnecessary when molecular genetics are accessible. If performed to rule out muscular dystrophy, it demonstrates muscle fiber hypertrophy, complete absence or severe paucity of type 2B fibers, and absence of necrotic fibers, internal nuclei, or endomysial fibrosis.

7. Classification

Accurate classification requires distinguishing myotonia congenita from other non-dystrophic channelopathies and multisystem dystrophic myotonias:

8. Treatment

Management of myotonia congenita requires a coordinated multimodal strategy incorporating medical membrane stabilization, physical therapy, and strict perioperative vigilance.

Medical / Pharmacologic Management

Pharmacotherapy is indicated when muscle stiffness, pain, or transient weakness interferes with activities of daily living, employment, or mobility:

• First-Line Agent: Mexiletine (Class IB Sodium Channel Blocker): State-dependent blocker of voltage-gated Nav1.4 sodium channels. By preferentially binding to open and inactivated channels, mexiletine suppresses repetitive myotonic afterdischarges without blunting single physiological action potentials.
  • Dosing: Initiate at 150 mg once or twice daily with meals; titrate weekly based on symptom control and tolerability up to 200 mg three times daily (maximum 600 mg/day).
  • Cardiovascular Monitoring: Mandatory baseline 12-lead electrocardiogram (ECG) to exclude pre-existing second- or third-degree atrioventricular block, intraventricular conduction delays, or prolonged QTc. Repeat ECG 2 to 4 weeks after dose titration.
  • Adverse Effects: Nausea, epigastric dyspepsia (minimized by taking with food), fine tremor, lightheadedness, and ataxia.
• Second-Line & Adjunctive Agents: When mexiletine is contraindicated, unavailable, or poorly tolerated:
  • Carbamazepine: 100 mg to 200 mg BID/TID; acts via sodium channel stabilization.
  • Lamotrigine: 25 mg to 100 mg daily; favorable tolerability profile with documented myotonia reduction.
  • Acetazolamide: 250 mg once to twice daily; carbonic anhydrase inhibition alters intracellular pH and potassium gradients, benefiting select patients.

Nonoperative & Physical Therapy

• Warm-Up Optimization: Educate patients to perform 5 to 10 minutes of low-intensity rhythmic movement (such as cycling or gentle walking) prior to demanding physical tasks, capitalizing on the physiological warm-up phenomenon.
• Contracture Prevention: Daily aggressive stretching of the gastrocnemius-soleus complexes, hamstrings, and hip flexors. Night splints and solid ankle-foot orthoses (AFOs) are employed in children presenting with dynamic equinus.
• Environmental Modification: Cold avoidance protocols including thermal compression apparel, heated garments, and workplace temperature regulation.

Operative & Perioperative Management

Primary surgical intervention is reserved for correcting secondary musculoskeletal deformities. However, perioperative anesthetic management is the most critical aspect of care:

• Achilles Tendon Lengthening: Indicated for fixed equinus contractures with ankle dorsiflexion 6 months of compliance with stretching, splinting, and medical optimization. Surgical options include percutaneous sliding Hoke tenotomy, open coronal Z-lengthening, or Vulpius/Strayer gastrocnemius recession if contracture is isolated to the gastrocnemius.
• MANDATORY ANCHOR: The Perioperative Channelopathy Protocol:
  • Absolute Contraindication to Succinylcholine: Depolarizing muscle relaxants trigger sustained, irreversible masseter spasm and generalized muscle contraction, rendering endotracheal intubation impossible and triggering life-threatening rhabdomyolysis and hyperkalemia.
  • Neuromuscular Blockade & Reversal: Use non-depolarizing neuromuscular blocking agents (e.g., rocuronium). Reversal must be achieved with sugammadex. Anticholinesterases (neostigmine) are strictly avoided because acetylcholinesterase inhibition increases acetylcholine concentration at the motor endplate, provoking severe myotonic spasms.
  • Thermal Regulation: Maintain core temperature strictly above 36.5°C using forced-air warming blankets and warmed intravenous fluids. Hypothermia and postoperative shivering induce intractable generalized myotonia.
  • Electrolyte Homeostasis: Avoid hypokalemia and metabolic acidosis, both of which lower the action potential threshold and aggravate channel instability.

Indications and Contraindications

• Indications for Surgery: Fixed, structural joint contractures (ankle dorsiflexion < 0°) causing functional gait impediment, intractable pain, or skin breakdown; traumatic fracture stabilization.
• Contraindications to Surgery: Dynamic toe-walking without structural contracture; surgery performed without direct anesthesiology briefing regarding channelopathy protocols; lack of active warming infrastructure.

9. Outcome

Data-driven therapeutic outcomes demonstrate favorable responses to targeted pharmacotherapy and structural orthopaedic corrections:

• Pharmacologic Response (Mexiletine): Multicenter randomized controlled trial evidence demonstrates that oral mexiletine produces statistically and clinically significant reductions in self-reported muscle stiffness (mean improvement of >2.9 points on a 0-to-10 visual analogue scale) and objective handgrip relaxation latency (mean reduction of 0.45 seconds). In randomized aggregated N-of-1 trials, mexiletine significantly improved patient-reported physical functioning, reduced daily pain, and alleviated chronic fatigue.
• Orthopaedic Deformity Correction: In pediatric patients undergoing Achilles tendon lengthening for fixed equinus, plantigrade foot position is achieved in >90% of cases, restoring heel-strike during early stance. Long-term maintenance of correction requires ongoing postoperative physiotherapy, night splinting, and medical management of myotonia to prevent recurrence.
• Functional Survivorship: Overall functional survivorship is excellent, with preservation of ambulation and employment throughout adult life in the vast majority of patients.

10. Complications

Complications span acute life-threatening perioperative crises, progressive structural deformities, and medication-induced toxicities:

11. Pearls and Pitfalls

Clinical Pearls

• The Warm-Up Hallmark: Diminution of stiffness with repetitive muscle contractions is the single most decisive clinical feature differentiating CLCN1 myotonia congenita from SCN4A paramyotonia congenita, where repetitive movements paradoxically aggravate stiffness.
• The Thenar Percussion Pearl: A quick bedside tap of the thenar eminence eliciting sustained thumb opposition/adduction provides instantaneous diagnostic verification in an orthopaedic clinic setting within 5 seconds.
• Absence of Dystrophic Stigmata: The presence of normal facial muscle contours, lack of early cataracts, normal cardiac conduction, and preserved muscle bulk distinguish myotonia congenita from myotonic dystrophy (DM1/DM2).
• The Reversal Rule: When general anesthesia is required for orthopaedic trauma or reconstructive surgery, mandate sugammadex for neuromuscular reversal; never administer neostigmine.

Clinical Pitfalls

• The Cerebral Palsy Misdiagnosis: Confusing a child’s stiff, toe-walking gait and prominent calf bulk with spastic diplegia (cerebral palsy), leading to inappropriate multilevel tenotomies or botulinum toxin injections.
• The Emergency RSI Disaster: Administering succinylcholine during emergency rapid sequence induction for an urgent fracture fixation in an undiagnosed myotonia congenita patient, resulting in catastrophic masseter spasm, impossibility of intubation, and hyperkalemic arrest.
• Over-lengthening Heel Cords: Performing aggressive Achilles tendon lengthening for dynamic contractures that would otherwise resolve with mexiletine and physical therapy, producing irreversible push-off weakness and crouch gait.

12. Controversy

Orphan Drug Pricing and Global Access to Mexiletine

Mexiletine represents the undisputed first-line pharmacologic treatment for non-dystrophic myotonias, corroborated by rigorous Level I randomized trials. However, the re-registration of mexiletine under orphan drug legislation in several jurisdictions has driven dramatic price increases, restricting patient access. Clinicians frequently encounter reimbursement hurdles, forcing reliance on older anti-seizure medications (such as carbamazepine or phenytoin) with less robust efficacy and greater side-effect profiles.

Interpretation of Variants of Uncertain Significance (VUS)

The CLCN1 gene exhibits extensive allelic heterogeneity, with over 300 unique mutations identified. Certain missense variants demonstrate incomplete penetrance, variable expressivity, or mixed inheritance patterns—acting in an autosomal dominant fashion in some pedigrees but recessive in others. Resolving whether a novel variant represents a benign polymorphism or a causative mutation requires specialized electrophysiological functional expression studies or meticulous multigenerational family segregation analysis.

Surgical vs. Conservative Management of Pediatric Equinus

In pediatric patients with Becker myotonia congenita presenting with toe-walking, there is active debate regarding the threshold for surgical tendon lengthening. While traditional orthopaedic paradigms advocate surgical lengthening when passive dorsiflexion remains limited, emerging neuromuscular evidence suggests that optimizing mexiletine therapy alongside intensive physical therapy can significantly reduce dynamic tone and restore plantigrade gait, potentially rendering surgical intervention unnecessary in a subset of patients.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Statland JM, Bundy BN, Wang Y et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA. 2012. doi:10.1001/jama.2012.12607 [Level I: Randomized Controlled Trial]
• Stunnenberg BC, Raaphorst J, Groenewoud HM et al. Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. JAMA. 2018. doi:10.1001/jama.2018.18020 [Level I: Randomized Controlled Trial (Aggregated N-of-1)]
• Koch MC, Steinmeyer K, Lorenz C et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. 1992. doi:10.1126/science.1379744 [Level II: Comparative Genetic Linkage & Mutational Study]
• Trivedi JR, Bundy B, Statland J et al. Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain. 2013. doi:10.1093/brain/awt133 [Level II: Prospective Longitudinal Cohort Study]
• Kwieciński H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand. 1992. doi:10.1111/j.1600-0404.1992.tb05103.x [Level I: Randomized Controlled Trial]

15. Master Class Pro-Tip

The Anesthetic Alert Rule in Suspected Musculoskeletal Channelopathy: Never administer succinylcholine or allow patient hypothermia in any individual presenting with unexplained ‘herculean’ calf hypertrophy, persistent toe-walking, or percussion myotonia. In elective orthopaedic procedures requiring soft-tissue correction, communicate directly with the anesthesia team to mandate non-depolarizing neuromuscular blockade reversed exclusively with sugammadex, maintain continuous active warming (>36.5°C), and obtain a baseline 12-lead electrocardiogram before commencing mexiletine therapy.

Master Class Surgical Pearl: Channelopathy Recognition and Anesthetic Safety